DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

Exclusion Criteria

• •The pathological type is mixed type, containing small cell carcinoma or other types of components.
• •with the blood-borne infectious disease HIV.
• •History of mental disorder, drug abuse and drug abuse.
• •Any other malignancy (except completely cured cervical carcinoma in situ or basal cell or squamous cell skin cancer) within 3 years.
• •Accompanied by other immune diseases, or long-term use of immunosuppressive agents or hormones.
• •Any unstable systemic disease (including active uncontrolled gastrointestinal ulcers, gastric obstruction, bleeding risk or coagulopathy, active infection, for subjects with hepatitis B, anti-hepatitis B 11 virus treatment is required during study treatment, active hepatitis C subjects (HCV antibody positive and HCV- RNA levels above the lower limit of detection, grade IV hypertension, unstable angina pectoris, congestive heart failure, myocarditis, unstable cerebrovascular disease, thrombotic disease, liver, kidney, uncontrolled metabolic disease or unhealed fractures, wounds as judged by the surgeon).
• •Presence of active central nervous system (CNS) metastases; subjects with previously treated brain metastases (e.g., surgery, radiotherapy, hormone therapy) are allowed if clinically stable for at least two weeks after treatment from the first dose of study drug and corticosteroids are discontinued 7 days before study drug administration; untreated, asymptomatic subjects with brain metastases (i.e., no neurological symptoms, no need for corticosteroids, no significant edema around the brain metastases) can be enrolled.
• •Any anti-tumor therapy including chemotherapy, radiotherapy, and targeted therapy within 3 weeks prior to the first dose of study drug.
• •Presence of pleural effusion, pericardial effusion, or ascites with clinical symptoms or requiring drainage.
• •Previous use of anti-tumor vaccines, live vaccines within 30 days.
• •Patients are difficult to communicate or to follow up for a long time. Pregnant or lactating women.
• •Current or planned participation in other clinical trials.
• •Dr. finds other unsuitable situations